home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Diabetes: Compound Stops Islet Destruction

  September, 5 2001 19:27
your information resource in human molecular genetics
Type I diabetes, in which the beta cells of the pancreas produce too little or no insulin, accounts for 3% of all new cases of diabetes each year. While the routine treatment for this disease is injections of insulin, an international team of scientists may have discovered a potentially new therapy for the condition (Nature Medicine, Vol. 7, No. 9, Sep 01).

One feature of Type 1 diabetes is a decrease in the number of Natural Killer T (NKT) cells of the immune system. This deficit also occurs in a mouse model of diabetes known as the NOD, or non-obese diabetic mouse model. The compound alpha-galactosylceramide (a-GalCer), binds to receptors on NKT-cells called CD1d receptors, and stimulates the production of cytokines from NKT-cells.

When they administered a-GalCer to NOD mice, the scientists found that it protected mice from developing diabetes even when given after onset of insulitis, and prolonged the survival of insulin-producing pancreatic islets transplanted into newly diabetic mice. In addition, a-GalCer enhanced the response to, and production of, vital cytokines by NKT cells.

The authors propose that a-GalCer decreases the destruction of islet cells by the body's own immune system and may have beneficial effects in diabetic patients.


Dr. Terry Delovitch
Department of Microbiology and Immunology
University of Western Ontario
London, Ontario, Canada
Tel: +1 519-663-3972
Fax: +1 519-663-3847
Email: del@rri.on.ca

Dr. Jean-François Bach
Institut National de la Santé
Centre de l'Association Claude Bernard
Hôpital Necker
61 rue de Sèvres
Paris Cedex 15, France
Tel: +33 1 444 9 5371
Fax: +33 1 4306 2388
E-mail: bach@necker.fr

Dr. Luc Van Kaer
Howard Hughes Medical Institute
Department of Microbiology and Immunology
Vanderbilt University School of Medicine
Nashville, Tennessee
Tel: +1 615 343 2707
Fax: +1 615 343 2972
Email: vankael@ctrvax.vanderbilt.edu

(C) Nature Medicine press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.